81
Views
67
CrossRef citations to date
0
Altmetric
Article

Renal replacement therapy in Sweden

, , , &
Pages 332-339 | Received 11 Feb 2004, Accepted 16 Mar 2004, Published online: 09 Jul 2009
 

Abstract

Objective: The Swedish Registry for Active Treatment of Uraemia (SRAU) was founded in 1991 with the objective of documenting demographic data on patients treated for end‐stage renal disease (ESRD). The aim of this study was to describe the prevalence, incidence, comorbidity risk factors and survival of patients with ESRD who underwent dialysis treatment and/or kidney transplantation in Sweden between 1991 and 2002.

Material and Methods: All dialysis and transplant units (n=65) presently report to the SRAU and almost all patients are reported and followed until death.

Results: The prevalence of patients on dialysis and transplantation, being ≈750 per million population (PMP), has increased by 75% in 12 years. The recent annual rise is ≈3% (200 patients). The incidence has been stable since 1997 at ≈125 patients PMP. In 2002, there were 1113 new patients, the majority of whom were aged ≥65 years. Their original kidney disease was most often diabetic nephropathy (23.7%), with nephrosclerosis (19.0%) being the second most common disease. The total number of renal transplantations performed has decreased to some extent. The overall 5‐year patient survival rate was 23.1% in patients on dialysis and 85.5% after kidney transplantation. The major cause of death was cardiovascular disease (48%) and an increasing frequency of malignancy after transplantation (26%) was noted.

Conclusion: The prevalence of ESRD has nearly doubled since 1990 and the number of new patients being referred for dialysis has increased. These patients are becoming older, with a large proportion having non‐renal complicating diseases. Survival after transplantation was excellent. The shortage of cadaveric donors in Sweden in recent years and increasing mortality from malignant disease after transplantation are issues of great concern.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.